Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery

Endocrine Journal

Volumn 56, Issue 2, 2009, Pages 245-249

  Noguchi, Hitoshi ^a   Yamashita, Hiroto ^a   Murakami, Tsukasa ^a   Hirai, Keisuke ^a   Noguchi, Yasushi ^a   Maruta, Junko ^a   Yokoi, Tadao ^a   Noguchi, Shiro ^a  

^a Hospital Foundation   (Japan)

Author keywords

Anaplastic carcinoma; HDAC; Thyroid; Valproic acid

Indexed keywords

AMMONIA; CISPLATIN; CREATININE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; VALPROIC ACID;

ADULT; AGRANULOCYTOSIS; AMMONIA BLOOD LEVEL; ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; CLUSTER HEADACHE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE CLEARANCE; DIZZINESS; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; EXTERNAL BEAM RADIOTHERAPY; HAIR LOSS; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; INTRAOPERATIVE RADIOTHERAPY; MALE; METASTASIS; MIGRAINE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PARESTHESIA; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RADIATION DOSE; REBOUND; SIDE EFFECT; SMELL HYPERSENSITIVITY; SMELLING DISORDER; TASTE DISORDER; THYROID CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; TREATMENT OUTCOME; WHOLE BODY PET;

CARCINOMA; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; HUMANS; MALE; MIDDLE AGED; THYROID GLAND; THYROID NEOPLASMS; TREATMENT OUTCOME; VALPROIC ACID;

EID: 66849128440     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K08E-016     Document Type: Article

References (8)

1. Are C, Shaha AR (2006) Anaplastic thyroid carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches. Annals of Surgical Oncology 13(4): 453-164.
2. Cornett WR, Sharma AK, Fernandes JK, et al. (2007) Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 9(2): 152-158.
3. Shen WT, Wong TS, Clark OH, et al. (2005) Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery 138(6): 979-984; discussion 984-985.
4. Catalano MG, Fortunati N, Pegliese M, et al. (2006) Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 191(2): 465-472.
5. Santini V, Gozzini A, Ferrari G (2007) Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application. Curr Drug Metab 8(4): 383-393.
6. Aurora A, Pandini G, Frasca F, et al. (2006) Peroxiso- mal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology 147(9): 4463-4475.
7. Zhang Y, Jia S, Liu Y, et al. (2007) A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun 28(4): 251-255.
8. Kim WG, Kim EY, Kim TY, et al. (2009) Redif- ferentiation Therapy with 13-cis Retinoic Acids in Radioiodine-Resistant Thyroid Cancer. Endocrine J 56: 105-112.